This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Recombinant Cholera Toxin B Subunit
DrugBank Accession Number
DB11643
Background

Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Cholera enterotoxin B chain
  • Cholera enterotoxin subunit B
  • Choleragenoid

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DukoralRecombinant Cholera Toxin B Subunit (1 mg) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (31250000000 bacteria) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (31250000000 bacteria)OralValneva Sweden Ab2022-06-08Not applicableEU flag
DukoralRecombinant Cholera Toxin B Subunit (1 mg) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (31250000000 bacteria) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (31250000000 bacteria)OralValneva Sweden Ab2022-06-08Not applicableEU flag
DukoralRecombinant Cholera Toxin B Subunit (1 mg) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (31250000000 bacteria) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (31250000000 bacteria) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (31250000000 bacteria)OralValneva Sweden Ab2022-06-08Not applicableEU flag
DukoralRecombinant Cholera Toxin B Subunit (1 mg / dose) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (31250000000 cells / dose) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (31250000000 cells / dose) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (31250000000 cells / dose) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (31250000000 cells / dose)SuspensionOralValneva Sweden Ab2003-04-15Not applicableCanada flag
DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEARecombinant Cholera Toxin B Subunit (1 mg) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (25000000000 unit) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (25000000000 unit) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (25000000000 unit) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (25000000000 unit)SuspensionOralAENON PHARMACEUTICALS SEA PTE. LTD.2003-02-06Not applicable
ดูโคราลRecombinant Cholera Toxin B Subunit (1 mg) + Vibrio cholerae Inaba 48 classical biotype, heat inactivated (2500000000 CFU) + Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated (2500000000 CFU) + Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated (2500000000 CFU) + Vibrio cholerae Ogawa 50 classical biotype, heat inactivated (2500000000 CFU)SuspensionOralบริษัท ไบโอจีนีเทค จำกัด2015-11-10Not applicableThailand flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1FKD81GIZJ
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionImmunity / Kidney Transplantation1
2TerminatedTreatmentUlcerative Colitis1
1CompletedBasic ScienceInfection1
1CompletedPreventionInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedNot AvailableVaccine Response Impaired1
Not AvailableCompletedPreventionCholera (Disorder) / Diarrhea1
Not AvailableCompletedPreventionInfection2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral
SuspensionOral1 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 17, 2016 21:30 / Updated at June 12, 2020 16:53